中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

19 records (took 0.024 seconds)

    INDOLO[2,1-b]QUINAZOLINE-6,12-DIONE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF
    2.
    发明申请
    INDOLO[2,1-b]QUINAZOLINE-6,12-DIONE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF 审中-公开
    吲哚[2,1-b]喹唑啉-6,12-二酮抗菌化合物及其使用方法

    公开(公告)号：WO1995013807A1

    公开(公告)日：1995-05-26

    申请号：PCT/US1994013259

    申请日：1994-11-17

    Applicant: PATHOGENESIS CORPORATION ,  BAKER, William, R. ,  MITSCHER, Lester, A.

    Inventor： PATHOGENESIS CORPORATION

    IPC: A61K31/38

    CPC classification number: C07D471/14 ,  C07D487/04 ,  C07D487/14 ,  C07D495/14 ,  C07D513/14

    Abstract: Methods, compounds and compositions are provided from inhibiting the growth of pathogenic mycobacteria in vitro and of treatment of pathogenic mycobacterial infections in vivo using indolo[2,1-b]quinazoline-6,12-dione compounds of formula (I), wherein A, B, C, D, E, F, G and H are independently selected from carbon and nitrogen, or A and B or C and D can be taken together to be nitrogen or sulfur, and the pharmaceutically acceptable salts thereof. The methods, compounds and compositions are particularly useful for inhibiting the growth of Mycobacterium tuberculosis, and may be used alone, or in combination with other anti-Mycobacterium tuberculosis agents, such as isoniazid, rifampin, pyrazinamide, rifabutin, streptomycin and ciprofloxacin, to provide new agents for the treatment of tuberculosis, including multidrug-resistant tuberculosis (MDRTB).

    Abstract translation: 方法，化合物和组合物是通过体外抑制致病性分枝杆菌的生长和体内使用式（I）的吲哚并[2,1-b]喹唑啉-6,12-二酮化合物治疗致病性分枝杆菌感染而提供的，其中A ，B，C，D，E，F，G和H独立地选自碳和氮，或A和B或C和D可以一起为氮或硫，以及其药学上可接受的盐。 方法，化合物和组合物特别可用于抑制结核分枝杆菌的生长，并且可以单独使用或与其它抗结核分枝杆菌结合剂如异烟肼，利福平，吡嗪酰胺，利福布丁，链霉素和环丙沙星组合使用，以提供 用于治疗结核病的新药物，包括多重耐药性结核病（MDRTB）。

    METHODS FOR ENRICHING TARGET NUCLEIC ACID SEQUENCES
    4.
    发明申请
    METHODS FOR ENRICHING TARGET NUCLEIC ACID SEQUENCES 审中-公开
    用于增强目标核酸序列的方法

    公开(公告)号：WO1997037042A1

    公开(公告)日：1997-10-09

    申请号：PCT/US1997004608

    申请日：1997-03-21

    Applicant: PATHOGENESIS CORPORATION ,  PARKER, Jay, D. ,  SMITH, Kirsten, T. ,  CHALLONER, Peter, B.

    Inventor： PATHOGENESIS CORPORATION

    IPC: C12Q01/68

    CPC classification number: C12Q1/6806 ,  C12N15/1072 ,  C12Q2600/158

    Abstract: The invention includes selective amplification methods for enriching target nucleic acid sequences that are present in a first source of nucleic acid but absent from a second source of nucleic acid. These methods involve using phenol to enhance the rate of the hybridization step, as well as modifications for reducing the amounts of reagents required for the reactions. Also included are methods for identifying sequences shared by two or more populations of nucleic acids.

    Abstract translation: 本发明包括用于富集靶核酸序列的选择性扩增方法，所述靶核酸序列存在于第一核酸源但不存在于第二核酸源中。 这些方法涉及使用苯酚来提高杂交步骤的速率，以及减少反应所需试剂量的修饰。 还包括用于鉴定两个或多个核酸群体共享的序列的方法。

    NITROIMIDAZOLE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF
    6.
    发明申请
    NITROIMIDAZOLE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF 审中-公开
    硝基吡唑类抗生素化合物及其使用方法

    公开(公告)号：WO1997001562A1

    公开(公告)日：1997-01-16

    申请号：PCT/US1996010904

    申请日：1996-06-25

    Applicant: PATHOGENESIS CORPORATION ,  BAKER, William, R. ,  SHAOPEI, Cai ,  KEELER, Eric, L.

    Inventor： PATHOGENESIS CORPORATION

    IPC: C07D498/00

    CPC classification number: C07D487/04 ,  Y02A50/488

    Abstract: Method, compounds and compositions are provided for inhibiting the growth of pathogenic microbes in vitro and of treatment of pathogenic bacterial infections, such as mycobacterial, Clostridium, Cryptosporidium and Helicobacter infections, in vivo using bicyclic nitroimidazole compounds. The methods, compounds and compositions are particularly useful for inhibiting the growth of Mycobacterium tuberculosis, Clostridium difficile, Cryptosporidium parvum, and Helicobacter pylori, and may be used alone, or in combination with other antimicrobial agents.

    Abstract translation: 提供方法，化合物和组合物用于在体内使用双环硝基咪唑化合物在体内抑制病原微生物在体外的生长和治疗病原性细菌感染，如分枝杆菌，梭菌，隐孢子虫和幽门螺杆菌感染。 方法，化合物和组合物特别可用于抑制结核分枝杆菌，艰难梭菌，隐孢子虫和幽门螺杆菌的生长，并且可以单独使用或与其它抗微生物剂组合使用。

    MICOBACTERIAL REPORTER STRAINS AND USES THEREOF
    9.
    发明申请
    MICOBACTERIAL REPORTER STRAINS AND USES THEREOF 审中-公开
    微生物报告物菌株及其用途

    公开(公告)号：WO1996010645A1

    公开(公告)日：1996-04-11

    申请号：PCT/US1995012642

    申请日：1995-10-02

    Applicant: PATHOGENESIS CORPORATION

    Inventor： PATHOGENESIS CORPORATION ,  STOVER, Kendall ,  HICKEY, Mark, J.

    IPC: C12Q01/66

    CPC classification number: C12N9/0069 ,  C12N15/74 ,  C12Q1/02 ,  C12Q1/6897

    Abstract: This invention relates to a method of quantifying bacteria in vivo or in vitro using bacterial reporter strains. In particular this invention provides a method utilizing mycobacterial reporter strains that permits rapid screening for in vivo antimycobacterial activity of various compositions. In addition this invention provides for particular mycobacterial reporter strains expressing the FFlux gene at levels sufficiently high to allow detection in tissue homogenates without lysis or concentration of the bacteria.

    Abstract translation: 本发明涉及使用细菌报道菌株在体内或体外定量细菌的方法。 特别地，本发明提供了利用分枝杆菌报道菌株的方法，其允许快速筛选各种组合物的体内抗分枝杆菌活性。 此外，本发明提供了表达FFlux基因的特异性分枝杆菌报道菌株，其水平足够高以允许在组织匀浆中检测而不裂解或浓缩细菌。

Patent Agency Ranking